Frontline Dasatinib Treatment in a 'Real-Life' Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
| Autor: | Raffaele Porrini, Monica Bocchia, Fabio Stagno, Patrizia Pregno, Elisabetta Abruzzese, Attilio Guarini, Agostino Antolino, Mario Tiribelli, Antonella Russo Rossi, Nicola Sgherza, Malgorzata Monika Trawinska, Sabrina Leonetti Crescenzi, Gianantonio Rosti, Fausto Castagnetti, Luigiana Luciano, Massimo Breccia, Monica Crugnola, Isabella Capodanno, Roberto Latagliata, Carmen Fava, Sara Galimberti, Massimiliano Bonifacio, Costanzo Feo, Giuliana Alimena, Manuela Rizzo, Endri Mauro, Federica Sorà, Paolo Vigneri, Alessandra Iurlo, Mario Annunziata, Antonella Gozzini |
|---|---|
| Přispěvatelé: | Latagliata, Roberto, Stagno, Fabio, Annunziata, Mario, Abruzzese, Elisabetta, Iurlo, Alessandra, Guarini, Attilio, Fava, Carmen, Gozzini, Antonella, Bonifacio, Massimiliano, Sorà, Federica, Leonetti Crescenzi, Sabrina, Bocchia, Monica, Crugnola, Monica, Castagnetti, Fausto, Capodanno, Isabella, Galimberti, Sara, Feo, Costanzo, Porrini, Raffaele, Pregno, Patrizia, Rizzo, Manuela, Antolino, Agostino, Mauro, Endri, Sgherza, Nicola, Luciano, Luigiana, Tiribelli, Mario, Russo Rossi, Antonella, Trawinska, Malgorzata, Vigneri, Paolo, Breccia, Massimo, Rosti, Gianantonio, Alimena, Giuliana |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Original article
Cancer Research medicine.medical_specialty Dasatinib Fusion Proteins bcr-abl Antineoplastic Agents Kaplan-Meier Estimate elderly patients lcsh:RC254-282 Cohort Studies 03 medical and health sciences 0302 clinical medicine chronic myeloid leukemia Leukemia Myelogenous Chronic BCR-ABL Positive Internal medicine medicine Humans Intensive care medicine Protein Kinase Inhibitors In Situ Hybridization Fluorescence Aged Aged 80 and over chronic myeloid leukemia dsatinib elderly patients dsatinib business.industry Myeloid leukemia lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Chromosome Banding Clinical trial Settore MED/15 - MALATTIE DEL SANGUE Leukemia Treatment Outcome 030220 oncology & carcinogenesis Concomitant Toxicity Cohort Neoplasm Grading business Follow-Up Studies 030215 immunology medicine.drug Cohort study |
| Zdroj: | Neoplasia (New York, N.Y.) Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 536-540 (2016) |
| Popis: | Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a "real-life" cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|